Edition:
United States

Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

16.30USD
12:47pm EDT
Change (% chg)

$-0.11 (-0.67%)
Prev Close
$16.41
Open
$16.44
Day's High
$16.46
Day's Low
$15.92
Volume
11,234
Avg. Vol
87,440
52-wk High
$20.60
52-wk Low
$3.40

Latest Key Developments (Source: Significant Developments)

Rocket Pharmaceuticals Prices Public Offering Of Common Stock
Wednesday, 24 Jan 2018 08:25am EST 

Jan 24 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $13.25PER SHARE.  Full Article

Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals
Thursday, 12 Oct 2017 05:20pm EDT 

Oct 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals.Inotek Pharmaceuticals Corp - ‍additional first-in-human results from up to three programs expected in 2018​.Inotek Pharmaceuticals Corp - ‍merger is expected to close in Q1 of 2018​.  Full Article

Citadel Advisors LLC reports 6.5 pct passive stake in Inotek Pharmaceuticals Corp
Monday, 29 Aug 2016 12:18pm EDT 

Inotek Pharmaceuticals Corp : Citadel Advisors LLC reports 6.5 percent passive stake in Inotek Pharmaceuticals Corp, as of August 22, 2016 - Sec filing Source - http://bit.ly/2bwMi6x Further company coverage: [ITEK.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Inotek Pharmaceuticals says completion of recruitment phase of Matrx-1
Wednesday, 24 Aug 2016 07:00am EDT 

Inotek Pharmaceuticals : Announces completion of recruitment phase of Matrx-1, first phase 3 clinical trial of Trabodenoson for glaucoma . Top-line data from Matrx-1 study are expected in december 2016. .Says top-line data from Matrx-1 study are expected in December 2016.  Full Article

Inotek Pharmaceuticals reports Q2 loss per share $0.33
Wednesday, 10 Aug 2016 07:00am EDT 

Inotek Pharmaceuticals Corp : Inotek Pharmaceuticals Corporation reports second quarter 2016 financial results and operational highlights . Q2 loss per share $0.33 .Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.  Full Article

Inotek announces pricing of $50 mln convertible senior notes
Tuesday, 2 Aug 2016 07:01am EDT 

Inotek Pharmaceuticals Corp :Inotek pharmaceuticals announces pricing of $50.0 million of 5.75 percent convertible senior notes due 2021.  Full Article

Inotek Pharmaceuticals announces offering of $50 mln of convertible senior notes
Monday, 1 Aug 2016 07:01am EDT 

Inotek Pharmaceuticals Corp: Inotek Pharmaceuticals announces proposed public offering of $50 million of convertible senior notes due 2021 . To use proceeds from offering to fund continued testing of trabodenoson as a monotherapy and as a fixed-dose ombination with latanoprost .Offering includes grant to underwriters of 30-day option to purchase up to additional $7.5 million aggregate principal amount of notes.  Full Article

Inotek Pharmaceuticals reports Q1 net loss of $10.1 mln
Wednesday, 11 May 2016 07:00am EDT 

Inotek Pharmaceuticals Corp : Says to expect top line data from phase 3 matrx-1 study in Q4 of 2016 .Inotek Pharmaceuticals Corporation reports first quarter 2016 financial results and operational highlights.  Full Article

Photo

Rocket-control glitch delays launch of NASA's planet-hunting satellite

CAPE CANAVERAL, Fla. An 11th-hour technical glitch prompted SpaceX to postpone its planned launch on Monday of a new NASA space telescope designed to detect worlds beyond our solar system, delaying for at least 48 hours a quest to expand astronomers' known inventory of so-called exoplanets.